Loading...
•
Dec 31, 2024
NextCure Q4 2024 Earnings Report
NextCure reported its full year 2024 financial results, highlighting progress in its ADC program and a decrease in net loss compared to the previous year.
Key Takeaways
NextCure, Inc. reported a net loss of $55.7 million for the full year ended December 31, 2024, an improvement from the $62.7 million net loss in 2023. The company completed cohort 1 of its LNCB74 Phase 1 trial and expects its current cash resources to fund operations into the second half of 2026.
Completed cohort 1 of the Phase 1 trial of LNCB74 (B7-H4 ADC) in February 2025 and plans to initiate backfill cohorts in the second half of 2025.
Cash, cash equivalents, and marketable securities were $68.6 million as of December 31, 2024, expected to fund operations into the second half of 2026.
Net loss for the full year ended December 31, 2024, was $55.7 million, an improvement from $62.7 million in the prior year.
Research and development expenses decreased to $41.5 million in 2024 from $47.9 million in 2023, primarily due to lower costs on other programs and personnel-related costs.
NextCure
NextCure
Forward Guidance
NextCure anticipates continued progress in its LNCB74 program, including initiating backfill cohorts in the second half of 2025, and expects its current financial resources to fund operations into the second half of 2026.
Positive Outlook
- Expects current financial resources to fund operations into the second half of 2026.
- Plans to initiate backfill cohorts for LNCB74 in the second half of 2025.
- Preclinical non-oncology programs (NC181 and NC605) could lead to IND filings within 12 to 18 months if financial support is secured.
- LNCB74 (B7-H4 ADC) has potential as a therapeutic for multiple solid tumor indications.
- Dosed first patient in January 2025 in Phase 1 trial, clearing cohort 1 in February 2025 and currently dosing cohort 2.
Challenges Ahead
- Positive results in preclinical studies may not be predictive of the results of clinical trials.
- NextCure has a limited operating history and no products approved for commercial sale.
- NextCure has a history of significant losses.
- NextCure's ability to obtain additional financing on acceptable terms is uncertain.
- Risks related to clinical development, marketing approval, and commercialization exist.